Nanopaclitaxel
The unique nanoparticulate formulation of the most widely used anticancer drug, Paclitaxel is under development. Nanopaclitaxel was formulated to eliminate the safety issues associated with other approved Paclitaxel preparations, such as Taxol, which uses various detergents to help the Paclitaxel molecule dissolve in water. Solubility in water is essential for administering drugs into the bloodstream. Unfortunately, the detergents used in other Paclitaxel formulations can be toxic, requiring patients to receive additional medications to counteract those toxicities. Nanopaclitaxel overcomes this solubility issue with unique nanoparticulate drug release- and -delivery system. Nanopaclitaxel is safer than Taxol, as well as more effective in treating oncology patients as patients can take larger doses of Paclitaxel. This is due to the lack of detergents in the nanoparticulate formulation.

ALL-3
A number of research studies have discovered that epithelial growth factor receptor Her-2 gene (EGFR Her-2) is not only a growth factor receptor, but also a networking receptor. It plays a key role in malignant tumor cell transformation. ALL-3 is a new chemical entity of EGFR Her-2 inhibitor, selectively inhibiting Her-2 receptor for the treatment of oncology patients. Patent protection has been filed.